Oral Administration: Multivalent cation-containing drugs and mineral supplements (eg, calcium, magnesium, aluminum, iron), polymeric phosphate binders, sucralfate or antacids and highly buffered drugs reduce the uptake (absorption) of Ciprobay. Ciprobay should therefore be administered either 1-2 hrs before or at least 4 hrs after ingestion of the antacid.
Concurrent administration of Ciprobay and theophylline can cause an undesirable increase in the theophylline plasma concentration. Therefore, it is necessary to determine the serum theophylline concentrations at brief intervals during concurrent administration with theophylline.
IV Administration: On simultaneous IV administration of Ciprobay and barbiturate-containing narcotics, monitoring of cardiovascular function is indicated.
A transient rise in the concentration of serum creatinine was observed when Ciprobay and cyclosporin were administered simultaneously. Therefore, it is necessary to control the serum creatinine concentrations in these patients frequently (twice a week).
Most Important Incompatibilities: Ciprobay infusion solution, unless compatibility with other infusion solutions/drugs has been confirmed, must always be administered separately. The visual signs of incompatibility are precipitation, clouding and discoloration.
Incompatibility appears with all infusions/drugs that are physically or chemically unstable at the pH of the solutions (eg, penicillins, heparin solutions), especially on combination with solutions adjusted to an alkaline pH (pH of the Ciprobay infusion solutions: 3.9-4.5).